ABSTRACT
Accurate assessment of response to treatment in locally advanced disease and metastatic disease of colorectal cancers, which is the third most common type of cancer in men and the second most common in women worldwide, is important in terms of organ-sparing surgery. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) shows tumor viability differently magnetic resonance, CT or ultrasonography. With this aspect, PET/CT can predict pathological response much earlier than other imaging modalities for both cytotoxic and cytostatic treatments. In this review, it is aimed to provide summary information in the light of current data in evaluating the treatment response of FDG PET/CT.
References
1World Health Organization (WHO) GLOBOCAN database. Web sayfası: https://gco.iarc.fr/.
2Aykan NF, Yalçın S, Turhal NS, et al. Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial). Turk J Gastroenterol 2015;26:145-153.
3Kelloff GJ, Schilsky RL, Alberts DS, et al. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res 2004;10:3908-3918.
4Gollub MJ, Schwartz LH, Akhurst T. Update on colorectal cancer imaging. Radiol Clin North Am 2007;45:85-118.
5Rodriguez-Bigas MA. Surgical resection of primary colon cancer. In: Tanabe KK, Weiser M, Chen W, eds. UpToDate.
6Jalil O, Claydon L, Arulampalam T. Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer. J Gastrointest Cancer 2015;46:219-236.
7O'Connor OJ, McDermott S, Slattery J, et al. The Use of PET-CT in the Assessment of Patients with Colorectal Carcinoma. Int J Surg Oncol 2011;2011:846512.
8Pfannschmidt J, Bischoff M, Muley T, et al. Diagnosis of pulmonary metastases with helical CT: the effect of imaging techniques. Thorac Cardiovasc Surg 2008;56:471-475.
9Wiering B, Ruers TJ, Krabbe PF, et al. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007;14:818-826.
10Kim NK, Baik SH, Min BS, et al. A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2007;67:204-210.
11Clark JW, Grothey A. Systemic chemotherapy for nonoperable metastatic colorectal cancer: treatment recommendations. In: Goldberg RM, Savarase DM, eds. UpToDate.
12Maas M, Lambregts DM, Nelemans PJ, et al. Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment. Ann Surg Oncol 2015;22:3873-3880.
13Li QW, Zheng RL, Ling YH, et al. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study. Abdom Radiol (NY) 2016;41:1448-1455.
14Lee MA, Cho SH, Seo AN, et al. Modified 3-Point MRI-Based Tumor Regression Grade Incorporating DWI for Locally Advanced Rectal Cancer. AJR Am J Roentgenol 2017;209:1247-1255.
15Herbertson RA, Scarsbrook AF, Lee ST, et al. Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol 2009;64:225-237.
16Mittal BR, Senthil R, Kashyap R, et al. 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun 2011;32:789-793.
17Borasio P, Gisabella M, Billé A, et al. Role of surgical resection in colorectal lung metastases: analysis of 137 patients. Int J Colorectal Dis 2011;26:183-190.
18Pauwels EK, Coumou AW, Kostkiewicz M, et al. [¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy. Med Princ Pract 2013;22:427-437.
19Maffione AM, Marzola MC, Capirci C, et al. Value of (18)F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2015;204:1261-1268.
20Joye I, Deroose CM, Vandecaveye V, et al. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol 2014;113:158-165.
21Glazer ES, Beaty K, Abdalla EK, et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010;145:340-345.
22Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006;20:579-587.
23Metser U, You J, McSweeney S, et al. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol 2010;194:766-771.
24Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-1189.
25Even-Sapir E, Parag Y, Lerman H, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815-822.
26Schlag PM, Amthauer H, Stroszczynski C, et al. Einfluss der Positronenemissionstomographie auf die chirurgische Therapieplanung beim colorectalen Rezidivtumor [Influence of positron emission tomography on surgical therapy planning in recurrent colorectal cancer]. Chirurg 2001;72:995-1002.
27Guillem JG, Puig-La Calle J Jr, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18-24.
28Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-1490.
29Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006;47:1241-1248.
30De Geus-Oei LF, van Laarhoven HWM, Visser EP, et al. Chemotherapy response evaluation with 18F-FDG-PET in patients with colorectal cancer. Ann Oncol 2008;19:348-352.
31Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-395.
32Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006;65:412-425.
33Roh SH, Jung SA, Kim SE, et al. The Clinical Meaning of Benign Colon Uptake in (18)F-FDG PET: Comparison with Colonoscopic Findings. Clin Endosc 2012;45:145-150.
34Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-246.
